Bio-Techne acquires CyVek in $195M deal; Almirall transfers 719 staffers to AstraZeneca;

@FierceBiotech: AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal. Article | Follow @FierceBiotech

@JohnCFierce: Joined at the hip. RT @bradloncar: Len Schleifer mentioned Viehbacher axing. he's meeting with Weinberg soon, $REGN very committed to $SNY. | Follow @JohnCFierce

@DamianFierce: I've been off Twitter for a minute. Has anyone called for a $REGN breakup yet? | Follow @DamianFierce

@EmilyMFierce: ICYMI from FierceMedicalDevices: Boston Scientific faces first two federal trials for transvaginal mesh devices. Story | Follow @EmilyMFierce

> Astellas sinks deeper roots into Cambridge's hot R&D field with $1.2B discovery pact. Article

> Rand tallies a whopping $44B in biosimilar drug savings. Item

> Novo Nordisk ($NVO) builds blockbuster case with promising PhIII obesity data. Report

> Bio-Techne is buying CyVek, an immunoassay outfit, for $60 million in cash and up to $135 million in milestones. Story

> Now that it has completed its deal with AstraZeneca ($AZN), Almirall says it is transferring 719 staffers to the Big Pharma. Item

Medical Device News

@FierceMedDev: ReShape finally reveals pivotal obesity data ahead of FDA review. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger. Article | Follow @VarunSaxena2

@EmilyWFierce: New medical imaging device with scanner the size of an iPhone uses ultrasound chip to create 3-D images in real time. Story from MIT Technology Review | Follow @EmilyWFierce

> ReShape finally reveals pivotal obesity data ahead of FDA review. Story

> Blood loss app developer Gauss Surgical raises $1.5M in equity sale. Article

Pharma News

@FiercePharma: Top-read on FP Monday: AstraZeneca seals the deal for Almirall's respiratory meds. Article | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: The revamp continues at Takeda, as does its financial struggles. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Report: Orphan drugs to nab 19% of drug sales by 2020--if payers don't balk, that is. Article | Follow @CarlyHFierce

> Which drugs win the script popularity contest? Crestor, Synthroid and Nexium. Story

> Allergan discloses a secret admirer looking to make an offer. Could it be ... Actavis? More

Biotech Research News

> Three-drug combo kills Ewing sarcoma in mice. More

> Potential target for triple-negative breast cancer found. Story

> 3D stomach tissue grown from human stem cells. Item

> Mouse model shows genetics plays role in Ebola severity. Article

> Drug combo causes lung cancer cells to self-destruct. More

Pharma Manufacturing News

> GSK gets go-ahead for expansion at plant in Scotland. Item

> Forest recalls another 90,000-plus bottles of Bystolic. Report

> Chinese company takes over Boehringer U.S. plant as German drugmaker expands in China. More

> Chairman says Wockhardt has no plans to sell. Story

> Novartis cuts more jobs at U.S. consumer plant ahead of handing it off to GSK. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.